XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration, License, Co-Promotion and Other Commercial Agreements - Summary (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenues:        
Revenue $ 89,432 $ 102,215 $ 169,375 $ 170,945
Collaborative arrangements revenue        
Revenues:        
Revenue 89,423 77,322 163,868 143,474
Collaborative arrangement, other agreements        
Revenues:        
Revenue 305 323 659 1,270
Sale of active pharmaceutical ingredient        
Revenues:        
Revenue 9 24,893 5,507 27,471
Sale of active pharmaceutical ingredient Other        
Revenues:        
Revenue       3
AbbVie | Collaborative arrangement, co-promotion agreements        
Revenues:        
Revenue   1,239   1,239
AbbVie | North America | Collaborative arrangements revenue        
Revenues:        
Revenue 86,926 75,498 158,618 140,283
AbbVie | North America | Collaborative arrangement, collaboration and license agreements        
Revenues:        
Revenue 86,926 75,498 158,618 140,283
AbbVie | Europe and Other | Collaborative arrangement, collaboration and license agreements        
Revenues:        
Revenue 440 262 1,083 682
AstraZeneca | China, Hong Kong, and Macau | Collaborative arrangement, collaboration and license agreements        
Revenues:        
Revenue 187   519  
AstraZeneca | China, Hong Kong, and Macau | Sale of active pharmaceutical ingredient        
Revenues:        
Revenue 9   5,507  
Astellas Pharma Inc. | Japan | Collaborative arrangements revenue        
Revenues:        
Revenue   24,900   27,500
Astellas Pharma Inc. | Japan | Collaborative arrangement, collaboration and license agreements        
Revenues:        
Revenue 504   983  
Astellas Pharma Inc. | Japan | Sale of active pharmaceutical ingredient        
Revenues:        
Revenue   $ 24,893   $ 27,468
Alnylam | Collaborative arrangement, co-promotion agreements        
Revenues:        
Revenue $ 1,061   $ 2,006